178 related articles for article (PubMed ID: 37106163)
61. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
[TBL] [Abstract][Full Text] [Related]
62. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
Petrov JC; Wada M; Pinz KG; Yan LE; Chen KH; Shuai X; Liu H; Chen X; Leung LH; Salman H; Hagag N; Liu F; Jiang X; Ma Y
Leukemia; 2018 Jun; 32(6):1317-1326. PubMed ID: 29515236
[TBL] [Abstract][Full Text] [Related]
63. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Gill S; Tasian SK; Ruella M; Shestova O; Li Y; Porter DL; Carroll M; Danet-Desnoyers G; Scholler J; Grupp SA; June CH; Kalos M
Blood; 2014 Apr; 123(15):2343-54. PubMed ID: 24596416
[TBL] [Abstract][Full Text] [Related]
64. A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.
Schneider D; Xiong Y; Hu P; Wu D; Chen W; Ying T; Zhu Z; Dimitrov DS; Dropulic B; Orentas RJ
Front Oncol; 2018; 8():539. PubMed ID: 30524966
[TBL] [Abstract][Full Text] [Related]
65. CAR T-cells targeting FLT3 have potent activity against FLT3
Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
[TBL] [Abstract][Full Text] [Related]
66. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J; Schimmer RR; Koch C; Schneiter F; Fullin J; Lysenko V; Pellegrino C; Klemm N; Russkamp N; Myburgh R; Volta L; Theocharides AP; Kurppa KJ; Ebert BL; Schroeder T; Manz MG; Boettcher S
EMBO Mol Med; 2024 Mar; 16(3):445-474. PubMed ID: 38355749
[TBL] [Abstract][Full Text] [Related]
67. A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR; Cadilha BL; Herrmann M; Lesch S; Schmitt S; Stoiber S; Darwich A; Augsberger C; Brauchle B; Rohrbacher L; Oner A; Seifert M; Schwerdtfeger M; Gottschlich A; Rataj F; Fenn NC; Klein C; Subklewe M; Endres S; Hopfner KP; Kobold S
Leukemia; 2021 Aug; 35(8):2243-2257. PubMed ID: 33414484
[TBL] [Abstract][Full Text] [Related]
68. [Development and functional verification of CAR-T cells targeting CLL-1].
Chai X; Jin X; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):102-106. PubMed ID: 35381669
[No Abstract] [Full Text] [Related]
69. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Kittel-Boselli E; Soto KEG; Loureiro LR; Hoffmann A; Bergmann R; Arndt C; Koristka S; Mitwasi N; Kegler A; Bartsch T; Berndt N; Altmann H; Fasslrinner F; Bornhäuser M; Bachmann MP; Feldmann A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638268
[TBL] [Abstract][Full Text] [Related]
70. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.
Sánchez Martínez D; Tirado N; Mensurado S; Martínez-Moreno A; Romecín P; Gutiérrez Agüera F; Correia DV; Silva-Santos B; Menéndez P
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162920
[TBL] [Abstract][Full Text] [Related]
71. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
72. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.
Lin G; Zhang Y; Yu L; Wu D
Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33495835
[TBL] [Abstract][Full Text] [Related]
73. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
74. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
[TBL] [Abstract][Full Text] [Related]
75. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
John S; Chen H; Deng M; Gui X; Wu G; Chen W; Li Z; Zhang N; An Z; Zhang CC
Mol Ther; 2018 Oct; 26(10):2487-2495. PubMed ID: 30131301
[TBL] [Abstract][Full Text] [Related]
76. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia.
Cheng J; Ge T; Zhu X; Wang J; Zeng Y; Mu W; Cai H; Dai Z; Jin J; Yang Y; Hu G; Mao X; Zhou J; Zhu L; Huang L
Cancer Immunol Immunother; 2023 Jul; 72(7):2331-2346. PubMed ID: 36932256
[TBL] [Abstract][Full Text] [Related]
77. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
[TBL] [Abstract][Full Text] [Related]
78. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
79. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
Dao T; Xiong G; Mun SS; Meyerberg J; Korontsvit T; Xiang J; Cui Z; Chang AY; Jarvis C; Cai W; Luo H; Pierson A; Daniyan A; Yoo S; Takao S; Kharas M; Kentsis A; Liu C; Scheinberg DA
Blood; 2024 Feb; 143(6):507-521. PubMed ID: 38048594
[TBL] [Abstract][Full Text] [Related]
80. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A; Thomas M; Grünmeier R; Lesch S; Rohrbacher L; Igl V; Briukhovetska D; Benmebarek MR; Vick B; Dede S; Müller K; Xu T; Dhoqina D; Märkl F; Robinson S; Sendelhofert A; Schulz H; Umut Ö; Kavaka V; Tsiverioti CA; Carlini E; Nandi S; Strzalkowski T; Lorenzini T; Stock S; Müller PJ; Dörr J; Seifert M; Cadilha BL; Brabenec R; Röder N; Rataj F; Nüesch M; Modemann F; Wellbrock J; Fiedler W; Kellner C; Beltrán E; Herold T; Paquet D; Jeremias I; von Baumgarten L; Endres S; Subklewe M; Marr C; Kobold S
Nat Biotechnol; 2023 Nov; 41(11):1618-1632. PubMed ID: 36914885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
